During the last session, PTC Therapeutics Inc (NASDAQ:PTCT)’s traded shares were 2.23 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $29.55, reflecting an intraday gain of 2.28% or $0.66. The 52-week high for the PTCT share is $59.84, that puts it down -102.5 from that peak though still a striking 40.68% gain since the share price plummeted to a 52-week low of $17.53. The company’s market capitalization is $2.26B, and the average intraday trading volume over the past 10 days was 0.95 million shares, and the average trade volume was 1.09 million shares over the past three months.
PTC Therapeutics Inc (NASDAQ:PTCT) trade information
PTC Therapeutics Inc (PTCT) registered a 2.28% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.28% in intraday trading to $29.55, hitting a weekly high. The stock’s 5-day price performance is -5.17%, and it has moved by 18.01% in 30 days. Based on these gigs, the overall price performance for the year is -36.78%. The short interest in PTC Therapeutics Inc (NASDAQ:PTCT) is 11.4 million shares and it means that shorts have 12.96 day(s) to cover.
PTC Therapeutics Inc (PTCT) estimates and forecasts
Statistics show that PTC Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. PTC Therapeutics Inc (PTCT) shares have gone down -20.97% during the last six months, with a year-to-date growth rate less than the industry average at -64.36% against 11.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 33.50% this quarter and then jump 44.40% in the quarter after that. In the rating firms’ projections, revenue will decrease -35.30% compared to the previous financial year.
Revenue for the current quarter is expected to be $170.36 million as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to $149.01 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $220.38 million and $213.81 million respectively. In this case, analysts expect current quarter sales to shrink by -22.70% and then drop by -30.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -24.94%. While earnings are projected to return 26.07% in 2024, the next five years will return -9.51% per annum.
PTCT Dividends
PTC Therapeutics Inc is due to release its next quarterly earnings between April 25 and April 29. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
PTC Therapeutics Inc (NASDAQ:PTCT)’s Major holders
PTC Therapeutics Inc insiders own 2.83% of total outstanding shares while institutional holders control 112.78%, with the float percentage being 116.06%. FMR, LLC is the largest shareholder of the company, while 271 institutions own stock in it. As of Jun 29, 2023, the company held over 10.25 million shares (or 13.61% of all shares), a total value of $416.99 million in shares.
The next largest institutional holding, with 7.55 million shares, is of Vanguard Group Inc’s that is approximately 10.02% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $307.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of PTC Therapeutics Inc (PTCT) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 2.32 million shares. This amounts to just over 3.08 percent of the company’s overall shares, with a $94.41 million market value. The same data shows that the other fund manager holds slightly less at 1.92 million, or about 2.54% of the stock, which is worth about $77.9 million.
